A Randomized, Placebo Controlled, Double-Blind Phase II Study to Evaluate Safety, Immunogencitiy and Prevention of Infection with Mycobacterium tuberculosis (Mtb) of H56:IC31 in Healthy Adolescents
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs H56IC (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms A-043
- Sponsors Aeras
- 06 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment since design, sponsorship changed prior to initiation. No study procedures done
- 21 Mar 2018 According to a Statens Serum Institut media release, Statens Serum Institut (SSI) has been granted a sum of EUR 13.8 million from the European & Developing Countries Clinical Trial Partnership (EDCTP).
- 22 Jan 2018 Planned End Date changed from 30 Dec 2020 to 30 Jun 2021.